Head of R&D, USA
Rohit Duggal is an experienced industry-research leader who specializes in establishing and advancing cell therapy and immuno-oncology platforms for product development. He joined ONK therapeutics as Head of R&D, USA in October 2020.
Rohit has more than 22 years of industry experience that spans cellular immunotherapy, immuno-oncology, oncolytic virotherapy, translational oncology and antiviral drug discovery.
Prior to joining ONK, Rohit led the primary lymphocyte product development program at NantKwest, an innovative clinical-stage cellular-immunotherapy company.
Previously, he was at Sorrento Therapeutics, where he played a role in developing the immuno-oncology franchise that included next-generation NK cell product development.
Rohit started his industry career at Agouron Pharmaceuticals, now a subsidiary of Pfizer. He was responsible for working on antiviral and oncology programs from drug discovery, translational research through to delivering clinical candidates.
Rohit received his PhD from Texas A&M University, College Station, Texas, USA.